Primary Patency With Stenting Versus Balloon Angioplasty for Arteriovenous Graft Failure: A Systematic Review and Meta-Analysis.

Primary Patency With Stenting Versus Balloon Angioplasty for Arteriovenous Graft Failure: A Systematic Review and Meta-Analysis. J Invasive Cardiol. 2019 Dec;31(12):E356-E361 Authors: Marmagkiolis K, Iliescu C, Edupuganti MMR, Saad M, Boudoulas KD, Gupta A, Lontos N, Cilingiroglu M Abstract OBJECTIVES: To evaluate the efficacy of advanced stent technology in the management of failing arteriovenous grafts (AVGs). BACKGROUND: End-stage renal disease rates and the need for hemodialysis are increasing worldwide. AVG remains a common dialysis access site. Several techniques have been previously suggested to restore and preserve AVG patency. A quantitative evaluation and synthesis of this information are essential in elucidating the role of newer stent platforms for the management of failing AVG. METHODS: We performed a literature search using PubMed, Web of Science, and Embase from January 2006 to December 2017. Studies comparing the primary patency rates with stent placement vs balloon angioplasty alone in patients with failed AVGs were included. RESULTS: Seven studies with a total of 1109 patients met the inclusion criteria. The mean graft age was 2.89 years in the stent group and 3.29 years in the balloon angioplasty group. Stent placement was associated with improved primary patency rates compared with balloon angioplasty alone at short-term (3-month) follow-up (73.2% vs 42.6%, respectively; risk ratio [RR], 0.55; 95% confidence interval [CI], ...
Source: The Journal of Invasive Cardiology - Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Related Links:

CONCLUSION: This case demonstrates the possibility of arterial compression by an adjacent venous stent graft, especially in a patient with a thin habitus and a brachial-brachial arteriovenous graft. Detailed identification of the outflow vein anatomy before stent implantation is mandatory to avoid such a complication. PMID: 31825299 [PubMed - as supplied by publisher]
Source: The Journal of Vascular Access - Category: Surgery Tags: J Vasc Access Source Type: research
End-stage renal disease (ESRD) patients experiencing kidney failure typically require hemodialysis in order to artificially remove fluid and waste from blood and maintain appropriate electrolyte concentrations. For many patients on hemodialysis, an a...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Vascular Surgery Source Type: blogs
Introduction: Most of patients in Egypt with end stage renal disease (ESRD) are on hemodialysis because of the low rate of kidney transplantation due to legal, religious, and financial issues.
Source: European Journal of Vascular and Endovascular Surgery - Category: Surgery Authors: Source Type: research
Introduction - to assess the outcomes of plain balloon angioplasty versus stenting for the treatment of failed or malfunctioning haemodialysis arteriovenous grafts (AVGs) for chronic haemodialysis.
Source: European Journal of Vascular and Endovascular Surgery - Category: Surgery Authors: Source Type: research
Introduction - Vascular access is the lifeline for chronic hemodialysis patient. Although autogenous arteriovenous fistula is the most favorable type of access, some patients must rely on artificial grafts because of multiple factors, such as advanced age1.
Source: European Journal of Vascular and Endovascular Surgery - Category: Surgery Authors: Source Type: research
Paclitaxel-coated balloons and paclitaxel-eluting stents caused quite the stir for manufacturers and physicians this year, but an FDA approval this week marks a major step forward for this category of devices. The agency approved Medtronic's IN.PACT AV drug-coated balloon for the treatment of failing arteriovenous access in patients with end-stage renal disease (ESRD) undergoing dialysis. AV fistulae are created and used to enable hemodialysis for patients with ESRD. Over time, vessel restenosis limits the ability to use AV fistulae effectively. In order to restore function, patients often undergo one to three ...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news
Publication date: Available online 6 November 2019Source: Journal of Vascular and Interventional RadiologyAuthor(s): Scott O. Trerotola, Theodore F. Saad, Prabir Roy-Chaudhury, Lutonix AV Clinical Trial InvestigatorsAbstractPurposeTo present final, 2-year results of a randomized trial comparing paclitaxel-coated vs uncoated balloon angioplasty following vessel preparation with ultra–high-pressure percutaneous transluminal angioplasty (PTA) in hemodialysis arteriovenous fistulae (AVFs).Materials and MethodsTwenty-three sites enrolled 285 subjects with dysfunctional AVFs located in the arm. Before 1:1 randomization, su...
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
To perform a meta-analysis comparing target lesion primary patency rates at 6 months and 1 year, and major procedure-associated complications between drug-eluting balloon (DEB) and plain balloon angioplasty (PBA) for the treatment of arteriovenous fistula (AVF) or synthetic arteriovenous graft (AVG) stenosis.
Source: Annals of Vascular Surgery - Category: Surgery Authors: Tags: General Review Source Type: research
CONCLUSION: The Arch V SUPERA-LUX study is the first trial to evaluate whether SUPERA stent implantation and drug-coated balloon use can provide superior protection against restenosis compared to traditional angioplasty, bare metal stents and stent grafts in recurrent cephalic arch stenosis. Initial pilot results are encouraging but longer follow-up is required to truly test this technique. TRIAL REGISTRATION: This study is registered on ClinicalTrials.gov NCT03891693. PMID: 31621477 [PubMed - as supplied by publisher]
Source: The Journal of Vascular Access - Category: Surgery Tags: J Vasc Access Source Type: research
Concept Medical’s MagicTouch AVF might have the “magic touch” when it comes down to nabbing breakthrough device designations. The proposed indication for the latest breakthrough device designation is for the treatment of stenotic lesions of Arteriovenous Fistulae or Arteriovenous graft in the hemodialysis treatment of renal failure. Concept Medical said its first pilot study to investigate the safety and efficacy of Magic Touch PTA Sirolimus balloon was started in Singapore in 2018. Led by Principal Investigator, Dr. Tan Chieh Suai, a multi-disciplinary team of doctors ...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news
More News: Angioplasty | Baloon Angioplasty | Cardiology | Dialysis | Heart | Hemodialysis | Science | Study